Declassified in Part - Sanitized Copy Approved for Release 2013/10/30 : CIA-RDP80T00246A026800090001-5

INFORMATION REPORT INFORMATION REPORT

CENTRAL INTELLIGENCE AGENCY

This material contains information affecting the National Defense of the United States within the meaning of the Espionage Laws, Title 18, U.S.C. Secs. 793 and 794, the transmission or revelation of which in any manner to an unauthorized person is prohibited by law.

	SEC	CRET	50	X1-HUM
COUNTRY	Poland Polish Pharmaceutical Industry	REPORT DATE DISTR.	16 SEP 1957	50X1
DATE OF	·	NO. PAGES REQUIREMENT NO. REFERENCES	5 RD	
PLACE & DATE ACQ.	SOURCE EVALUATIONS ARE DEFINITIVE.	APPRAISAL OF CONTEN	IT IS TENTATIVE.	50X1-HUN
				50X1-HUI

- 1. The Central Administration for the Pharmaceutical Industry (Centralny Zarzad Przemyslu Farmaceuticznego), which has 100 employees, is located at No. 3 Mysia Street, Warsaw, and is under the Ministry for the Chemical Industry. The Administration also maintains a Pharmaceutical Scientific Institute, with two branches, one at the Pharmaceutical Works at Tarchomin, and the other one at the Krakow Pharmaceutical Works. The central plant at Warsaw has some 200 employees. In 1956, a special department for the production of streptomycin was established at that plant.
- 2. The plants which are controlled by the Central Administration are of two types:
 - a. Plants preparing pharmaceutical products from basic materials.
 - b. Plants manufacturing medicaments and drugs.
- 3. The plants preparing pharmaceutical products from basic materials are as follows:
 - a. The Tarchomin Pharmaceutical Works (Tarchominskie Zaklady Farmaceutyczne), located at No. 19 Fabryczca Street, Tarchomin, which is the largest enterprise of its kind in Poland. It was put into operation immediately after World War II, using what had been left of the prewar plant of Spies i Synowie. Some 1,800 persons are employed, including 350 administrative personnel. The plant has three production divisions: for penicillin, for synthesis, and for medical preparations and injections. In addition to the above mentioned there are auxiliary divisions, such as a workshop, power station, and carpentry.

				SECI	RET	•/					5	0Χ1-HL
STATE	Х	ARMY	ΙX	NAVY	X	AIR	X	FBI .	AEC			
(Note: Washington distribution indicated by "X"; Field distribution by "#".)												

INFORMATION REPORT INFORMATION REPORT

SECRET	50X1 50X1-HUM
ent 2 text	


In January 1957, cultures were imported because these cultures were producing at a larger rate than the ones imported from the USSR. In 1956 the department produced 6,700 million units of penicillin; by 1957, with the use of Soviet-produced cultures, production rose to 800 million units, while after 50X1-HUM had been put to use, production was estimated at about 2,000 million units. The quality of the penicillin is not high. A number of foreign purchasers, mainly China, have complained of the low quality.


- (2) The Synthesis Division is the second largest in the plant. It manufactures barbiturates, Vitamin D₂, Acetarsol, Novarsan, Polocain. The equipments of the division dates back to prewar times. Only the "reactors" (Reaktory) were brought from Hungary and Germany after World War II. The products are not of the same quality. Acetarsol and Polocain are of high standard, the barbiturates do not come up to standard, Novarsan was taken off the market because of its poor quality and its production was discontinued. For the same reason, as well as because of high production costs, the production of Vitamin D₂ has also been discontinued. In 1956 the division manufactured 9,000 kg. of Polocain, and in 1957 it plans to manufacture 12,000 kg.
- (3) The Medicaments and Injections Division produces insulin and Hepafort, and, in addition, manufactures and divides into units preparations produced by other divisions. The equipment for the production of insulin and of Hepafort is modern. Insulin was produced on a commercial basis only in 1956. According to plan, 250 billion units of insulin will be produced in 1957. The quality, however, is poor.
- b. The Krakow Pharmaceutical Works (Krakowskie Zaklady Farmaceutyczne), which is located in the Podgorze district of Krakow. Established after World War II, it now employs 1,300-1,400 workers. The plant produces aureomycin and vitamins.
- c. The Pharmaceutical Works of Starogard, near Gdansk (Starogardskie Zaklady Farmaceutyczne), established after World War II, which employs 1,100 to 1,200 workers, and manufactures sulfonamides (Sulfamidy) (8 to 9 tons per annum).
- d. The Foch Works at Gliwice (Gleiwitz) (Fabryka Odczynnikow "Foch" Gliwice) which is a temporary, experimental plant, and employs 800 to 900 workers.
- e. Pabianice Chemical Works (Zaklady Przemyslu Chemicznego Pabianice).
- f. Kutno Pharmaceutical Works (Kutnowskie Zaklady Farmaceutyczne) which is a small, morphium-producing plant.
- 4. The plants which manufacture medicaments and drugs are as follows:
 - a. Warsaw Pharmaceutical Works (Warszawskie Zaklady Farmaceutyczne) on Karolkowa Street, Warsaw. This plant, formerly known as the Clave plant, employs some 1,000 workers, produces injectors, and manufactures medicaments from semifinished materials.
 - b. The Motor Pharmaceutical Works on Raclawicka Street, Warsaw (Zaklady Farmaceutyczne Motor W-Wa). This plant is made up of a number of former private enterprises expropriated by the government, such as: The Motor Works, Mokotow district, the Roztkowski Works at Radosc, near Warsaw, and another plant in the Wola district.

s	E.	C	R	E.	,TP	
						•

50X1-HUM

		•	•	
	4 . **	SECRET		50X1
				50X1-HUM
		. -3-	ŕ	
	c. The Jelenia Gora Pharmaceut a former German plant, which			naceutyczne),
:	d. The Lodz Pharmaceutical Work	ks (Lodzkie Zaklady F	'armaceutyczne), a	small
	e. The Chirurgofil Plant, at Powhich produces surgical yard Polish requirements, therefore imported.	n only. This plant i	is hot able to meet	all
5.	The following pertains to the inmaterials. In 1956 three tons at tons are scheduled to be imported vitamin B ₁₂ were imported year were: 12 tons of caffeine Hungary; large quantities of No Efforts are made to produce it	of streptomycin were ed in 1957. Large qu in 1956. Othe , from East Germany; varsan from the USSR,	imported unantitites of aurecer items imported in 18-20 kg. Vitamin however, of low of	myein and in the same D ₂ , from 50X1-HUM
6.	of penicillin were sold to China orders were placed by China for delivered had been of inferior to China in order to investigate be baseless. The real reason we to buy the cheaper Seven hundred billion units of perfect to Rumania were discontinuous solutions.	a (or 400 billion uni 1957, since it was of quality. Poland disp e this claim, which was apparently the fac penicillin powder a penicillin were expon inued as well, since	ts annually). No claimed that the persecution of the persecution of the control o	further enicillin commission sund to 50X1-HUM preferred aselves. 50X1-HUM Penicillin 50X1-HUM
	established a penicillin indust:			4.*
7.	In 1956 Poland exported four to		n the treatment of	50X1-HUM plague) 50X1-HUM
8.	Quantities of pharmaceutical pro	oduction:		
	a. Polocain: In 1956 the outpuse and four for export. The			
	b. Penicillin: The output for increased in 1957 to 20,000		on units, which is	s to be 50X1-HUM
	c. Sulfonamides (Sulfamidy):	The total output in F	Poland for 1956 was	40 tons.
	d. Insulin: Production target	for 1957 is 250 billi	on units.	
	e. Hepafort: The output for 1	956 was 5,000 liters.		
	f. Barbiturates: The output for anaesthetics). Production	or 1956 was 17 tons (target for 1957 is 20	sleeping pills and tons.	l local
9•	At Tarchomin, where the entire in new divisions will be added unto aureomycin, terramycin and streis also to be expanded, and will fermentation tanks.	il 1966, for the proc ptomycin. The penici l include the buildir	luction of Vitamin llin-producing div	B ₁₂ , vision
		ECRET		50X1-HUM





SECRET

50X1-HUM